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ABSTRACT
Inflammation is a significant risk factor for brain injury in the
perinatal period. In this study,we tested the hypothesis that
activation of peripheral TLR induces inflammation in the
brain, including leukocyte trafficking. Postnatal day 8 mice
were injected intraperitoneally with a TLR1/2 (Pam3CSK4,
P3C), TLR2/6 (FSL-1) or TLR4 (LPS) agonist, and the
peripheral and central cytokine and chemokine response
was determined. Infiltration of immune cells to the CSF and
brain was examined by flow cytometry, and brain perme-
ability was investigated by radioactively labeled sucrose.
We report that peripheral administration of P3C to neonatal
mice induces significant influx of leukocytes, mainly neu-
trophils and monocytes, to the CSF and brain. Infiltration of
leukocytes was TLR2 and MyD88 dependent, but largely
absent after administration of LPS or FSL-1. PC3-mediated
accumulation of immune cells in the brain was observed in
classic CNS-leukocyte gateways, the subarachnoid space
and choroid plexus, as well as in the median eminence.
Although P3C and LPS induced a similar degree of
peripheral inflammatory responses, P3C provoked a dis-
tinct brain chemokine response and increased permeabil-
ity, in particular, of the blood-CSF barrier. Collectively, our
results do not support the hypothesis that TLR activation, in
general, induces immune cell infiltration to the brain.
Instead, we have discovered a specific TLR2-mediated
mechanism of CNS inflammation and leukocyte invasion
into the neonatal brain. This interaction between peripheral
and central immune responses is to a large extent via the
blood-CSF barrier. J. Leukoc. Biol. 100: 000–000; 2016.
Introduction
Inﬂammation is increasingly understood to be an important risk
factor for neonatal brain injury and subsequent neurologic
syndromes, such as cerebral palsy [1, 2]. Proinﬂammatory
cytokines are elevated in the CSF of asphyxiated term infants,
and the level of inﬂammatory response reﬂects the degree of
hypoxic-ischemic encephalopathy [3]. Cytokines are also
elevated in newborns with severe intraventricular hemorrhage
and in the brains of neonates with white matter injury [4].
Under physiologic conditions, the CNS is protected from blood-
borne pathogens and immune cells by a physical BBB, which
consists of tight junctions between brain endothelial cells. In a
similar fashion, immune factors and circulating cells have
limited entry into the CSF by an epithelial cell barrier at the
choroid plexus [5]. These barriers are present and functioning
from an early age [6, 7]. Increased permeability of the BBB in
pathologic situations has been associated with brain injury [8,
9]; however, the degree of interaction between peripheral and
central immune responses via the BCSFB and the mechanisms
that underlie such communication remain, to a large extent,
enigmatic.
The TLR subfamily of pattern recognition receptors are a well-
characterized component of the innate immune system that
detects pathogen- and damage-associated molecular patterns and
initiate inﬂammatory responses [10]. We have previously shown
that systemic administration of TLR3 and TLR4 agonists to
newborn mice sensitize the brain to subsequent hypoxic-ischemic
brain injury [11, 12] and the TLR2-deﬁcient mice are protected
from neonatal hypoxia-ischemia [13]. Furthermore, repeated
systemic administration of the TLR1/2 agonist P3C impairs brain
development in neonatal mice [14]. In adult mice, intrathecal
injection of P3C causes neural loss and CSF pleocytosis [15].
Similarly, we have noted increased number of leukocytes in CSF
in neonatal mice after systemic P3C administration [16].
However, the systemic inﬂammatory response initiated in
response to TLR2 activation in newborns has not been fully
proﬁled, and its effect on the developing CNS remains largely
unknown.
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Here, we report for the ﬁrst time, to our knowledge, on the
systemic and cerebral inﬂammatory response, including cellular
characteristics, to TLR2 activation in neonatal mice. We
discovered TLR2- and MyD88-dependent leukocyte inﬁltration
into the CSF and brain after systemic administration of P3C. In
contrast, administration of TLR4 agonist, LPS, or TLR2/6
agonist, FSL-1, did not result in cell trafﬁcking into the CSF.
MATERIALS AND METHODS
Animals
C57Bl/6J mice were purchased from Charles River Laboratories (Wilmington,
MA, USA). TLR2 KO (B6.129-Tlr2tm1Kir/J) and MyD88 KO mice (B6.129P2
(SJL)-Myd88tm1.1Defr/J) were purchased from The Jackson Laboratory (Bar
Harbor, ME, USA). Lys-EGFP-ki mice were obtained from Dr. Tomas Graf,
Autonomous University of Barcelona (Barcelona, Spain). All transgenic
animals were maintained on a C57BL/6J background and were housed and
bred at the Laboratory for Experimental Biomedicine, University of
Gothenburg, with ad libitum access to food and water on a 12-h light-dark
cycle. Animal protocols were approved by the Gothenburg Animal Ethics
Committee.
Experimental procedures
Eight-day-old mice (PND8) were injected intraperitoneally with either the
TLR1/2 ligand P3C (Invivogen, Toulouse, France), the TLR4 ligand LPS
(Serotype 055:B5, ultra-pure; List Biologic Laboratory, Campbell, CA, USA),
or the TLR2/6 agonist FSL-1 (Invivogen). Dosages were 5 mg/kg or 1 mg/kg
for P3C, 1 mg/kg or 0.3 mg/kg for LPS, and 0.3 mg/kg for FSL-1, and all were
based on previous studies [4, 17]. Injection volume was 10 ml/g body weight.
In one experiment, adult mice were injected intraperitoneally with 1 mg/
kg P3C.
CSF collection and leukocyte count
Pups were killed at various time points after agonist administration by
injection of an overdose of sodium thiopental followed by an incision in the
heart. CSF (3–5 ml) was collected from the cisterna magna by using a ﬁne glass
capillary. CSF samples were discarded if any trace of blood contamination was
observed. Samples were stained with methyl violet or Turk’s solution, and cell
quantiﬁcation was performed with a Bu¨rker chamber.
Flow cytometry of leukocytes in CSF, blood, and brain
Pups were killed with thiopental sodium, and blood was collected from the
right ventricle and transferred to an EDTA-coated tube. RBCs were lysed by
using RBC Lysis Buffer (Sigma-Aldrich, Stockholm, Sweden) before staining.
CSF was collected as above, and for ﬂow cytometry analysis at the 6-h time
point, samples from 3 pups were pooled for each “n” as a result of the small
volume of CSF. Leukocytes from blood and CSF were washed with PBS and
pelleted by centrifugation at 400 g for 7 min at 4°C, then resuspended in PBS
that contained 0.5% bovine serum albumin and FC Block (BD Pharmingen,
Stockholm, Sweden) to block unspeciﬁc binding to FC receptors. Cells were
stained with CD45 APC-Cy7 (Clone 30-F11; BD Pharmingen), CD11b FITC
(Clone M1/70; eBiosciences, Stockholm, Sweden), Ly6C PE-Cy7 (Clone AL-
21; BD Pharmingen), Ly6G PE (Clone 1A8; BD Pharmingen), TCRb PE
(Clone H57-597; eBiosciences), CD19 FITC (Clone 1D3; BD Pharmingen),
and 7AAD (BD Pharmingen). Antibody amount was 0.2 mg per;106 cells, and
staining was performed at room temperature for 20 min. Flow cytometry was
performed by using BD FACSCanto (BD Bioscience, Stockholm, Sweden).
Gating strategy is shown in Fig. 2.
For ﬂow cytometry of brain tissue, pups were killed 14 h after agonist
administration by sodium thiopental overdose and perfused with saline for
2–3 min at a rate of 1 ml/min. Brains were cut into small pieces and washed
with PBS to remove CSF residuals and then dissociated by using MACS Neural
Tissue Dissociation Kit and gentleMACS Dissociator (Milteny Biotec, Lund,
Sweden) following standard protocol. Single-cell suspensions were pelleted as
above and resuspended in 30% Percoll solution (GE Healthcare, Pittsburgh,
PA, USA), and added on top of a layer of 70% Percoll. Percoll gradients were
centrifuged (950 g, 30 min, room temperature) and the enriched population
of leukocytes/microglia was collected at the 70–30% Percoll interphase [18].
Enriched samples were then washed, blocked, and stained with CD45 APC-
Cy7, CD11b FITC, and 7AAD for 30 min at 4°C. Single live cells were gated
and analyzed for expression of CD45 and CD11b. Data were analyzed by using
FlowJo (Tree Star, Ashland, OR, USA).
Immunohistochemistry
PND8 Lys-EGFP-ki mice were injected with P3C (5 mg/kg), LPS (0.3 mg/kg)
or saline (0.9%). Pups were killed 14 h after injection and transcardially
perfused with saline, followed by 4% paraformaldehyde. Brains were removed,
postﬁxed in paraformaldehyde for 24 h at 4°C, and cryoprotected in 30%
sucrose solution for at least 3 d. Cryoprotected brains were snap frozen on
liquid nitrogen and serially sectioned at 40 mm on a Leica CM3050S cryostat
(Leica, Wetzlar, Germany). Sections were stored in cryoprotectant solution
(25% ethylene glycol, 25% glycerine, in 0.1 M phosphate buffer) at 220°C.
Antigen retrieval was performed by 10 min incubation in 10 mM sodium
citrate (pH6, at 97°C), and nonspeciﬁc binding sites were blocked by 30 min
incubation in TBS that contained 3% donkey serum and 0.1% Triton X-100
(hereafter referred to as blocking buffer). Sections were then incubated
overnight at 4°C in blocking buffer that contained Alexa Fluor 488–
conjugated rabbit anti-GFP (1:200; Thermo Fisher Scientiﬁc), Mix-N-Stain
CF657 (Sigma-Aldrich) conjugated goat polyclonal anti-CD31 (1:200; R&D
Systems, Abingdon, United Kingdom), and rat monoclonal anti-Ly6G (1:250;
clone 1A8; Biolegend, San Diego, CA, USA) before being incubated with
donkey anti-rat CF555 (1:1000; VWR, Stockholm, Sweden) diluted in blocking
buffer for 1 h at room temperature. Images were captured by using a Zeiss
LSM 700 inverted confocal microscope equipped with Zen black software
(Zeiss, Oberkochen, Germany).
Multiplex cytokine assay
PND8 mice were injected with P3C (1 or 5 mg/kg, i.p.), LPS (0.3 or 1 mg/kg,
i.p.) or saline (0.9%, i.p.) and killed 6 h later. Blood was collected from the
right ventricle of the heart and transferred to EDTA-coated tubes and
spleens were dissected out. Animals were then transcardially perfused with
saline and brains were removed. Spleen and brain tissue samples were frozen
on dry ice immediately upon removal. Plasma was isolated from blood and
frozen on dry ice. Brains and spleens were lysed by using a Bio-Plex Cell Lysis
Kit (Bio-Rad, Hercules, CA, USA) plus 20% of 0.1 M PMSF (Sigma-Aldrich)
on ice and by applying sonication (40% amplitude 18 pulses each 1.2 s,
freeze and thaw, 10 pulses). Lysates were pelleted by centrifugation (4500 g,
5 min, 4°C) and stored at 280°C until use. Protein concentration was
measured by using a Pierce BCA Protein Assay Kit (Thermo Fisher
Scientiﬁc) following a standard protocol. Cytokine assay was performed by
using a Bio-Plex Pro Mouse Cytokine Standard 23-Plex kit (Bio-Rad)
following the manufacturer protocol, and cytokines were quantiﬁed on a
Bio-Plex 200 Systems. Plasma samples were diluted 1:4 in diluent buffer, and
brain and spleen samples were diluted 1:3 to load approximately 1–2 mg of
protein. Obtained data were normalized to protein concentration and
presented as Log10 of cytokine concentrations (picograms per milliliter for
plasma samples and picograms per milligram protein for brain and spleen
samples).
BBB and BCSFB permeability
Measurements of BBB and BCSFB permeability were performed as described
recently [1]. In brief, 10 h after P3C (5 mg/kg), LPS (0.3 mg/kg), or saline
injection, mice were injected intraperitoneally with [14C]sucrose (0.2 mCi/g;
American Radiolabeled Chemicals, St. Louis, MO, USA) and killed 30 min
later with an overdose inhalation of isoﬂurane. Blood was collected from the
heart and plasma was separated by centrifugation. CSF and different regions
of brain were collected (cortex, striatum/thalamus, cerebellum, and
2 Journal of Leukocyte Biology Volume 100, December 2016 www.jleukbio.org
brainstem). All tissues and ﬂuid samples were weighed. Radioactivity in
samples was measured by liquid scintillation counting and calculated as cpm/
mg. Tissue radioactivity was corrected for residual blood in tissues [8]. The
concentration ratios between CSF/plasma and brain tissue/plasma were
calculated as measures of BBB or BCSFB permeability.
Statistics
Data comparisons that involved .2 study groups (e.g., CSF leukocyte count,
blood and brain ﬂow cytometry, cytokine assay, and permeability test) were
performed by 1-way ANOVA, followed by either Dunnett’s or Tukey’s post hoc
tests. In Fig. 2H–J, comparisons between different doses of P3C were
performed with Student’s t test at each time point and corrected for multiple
comparisons in accordance with the Holm-Sidak method. CSF leukocyte
counts in adult TLR2 KO and MyD88 KO mice were compared by using
Student’s t test. Data are presented as means 6 SEM unleAQ:4 ss otherwise stated.
Statistical analysis was performed by using Prism V6.0 (GraphPad Software, La
Jolla, CA, USA), and Radar charts were made by using Excel (Microsoft,
Redmond, WA, USA).
RESULTS
P3C induces leukocyte inﬁltration into the CSF in a
TLR2- and MyD88-dependent manner
Peripheral administration of low and high doses of P3C to
neonatal mice induced substantial accumulation of leukocytes in
the CSF, an effect detected as early as 6 h after injection (1 mg/
kg: 418 6 34 leukocytes/ml; P , 0.05; 5 mg/kg: 510 6 111
leukocytes/ml; P , 0.001; compared with saline: 30 6 15, n =
5–10/group; Fig. 1A), peaking at 14 h (1 mg/kg: 3508 6 700
leukocytes/ml; P , 0.001; 5 mg/kg: 4378 6 842 leukocytes/ml; P
, 0.0001; compared with saline: 20 6 9, n = 5–10/group; Fig.
1B), and still slightly increased at 48 h (1 mg/kg: 156 6 32
leukocytes/ml; P , 0.01; 5 mg/kg: 153 6 24 leukocytes/ml; P ,
0.001; compared with saline: 12 6 12, n = 5–10/group; Fig. 1D).
In contrast, LPS at either low or high doses did not cause
signiﬁcant change in the number of leukocytes in CSF at 6, 14, or
24-h time points (P . 0.05; Fig. 1A–C); however, the high dose of
LPS (1 mg/kg) caused a slight, but signiﬁcant, elevation in CSF
leukocyte count at the 48-h time point (P , 0.05; Fig. 1D). It is
noteworthy that P3C caused similar effects in adult mice (1 mg/
kg: 2963 6 1290 leukocytes/ml vs. saline: 12 6 7 leukocyte/ml at
the 14-h time point; n = 3; P = 0.041). P3C injection in TLR2 KO
and MyD88 KO neonatal mice did not result in signiﬁcant
changes in CSF leukocyte numbers at 14 h (TLR2 KO: 40 6 20
leukocytes/ml; P = 0.24; MyD88 6 6 2 leukocytes/ml; P = 0.31;
compared with saline: 20 6 9 leukocytes/ml; n = 3/group; Fig.
1B). To test the effect of other TLR2 heterodimers, the TLR2-
TLR6 agonist FSL-1 was injected into neonatal mice. FSL-1 did
not result in CSF pleocytosis at the 14-h time point (20 6 20
leukocyte/ml vs. saline 20 6 9 leukocytes/ml; P = 0.94; n = 3/
group).
P3C-induced CSF inﬁltrating cells are mainly
neutrophils and monocytes
We next sought to characterize CSF inﬁltrating leukocytes by ﬂow
cytometry. Cells were gated ﬁrst on size and granularity (Fig. 2A),
B
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Figure 1. TLR1/2 activation induces inﬁltration of
leukocytes into the CSF. (A–D) PND8 mice were
injected with P3C (1 or 5 mg/kg, i.p.), LPS (0.3
or 1 mg/kg, i.p.), or saline, and leukocytes in the
CSF were counted at 6 h (A), 14 h (B), 24 h (C),
and 48 h (D). Data are presented as means 6 SD.
*P # 0.05; **P # 0.01; ***P # 0.001; ****P #
0.0001, 1-way ANOVA with Dunnett’s post hoc test
calculating the difference in relation to the saline
group (n = 5–10/group).
Mottahedin et al. TLR2-mediated leukocyte trafficking to the CNS
www.jleukbio.org Volume 100, December 2016 Journal of Leukocyte Biology 3
followed by gating on live and single cells (Fig. 2B and C). Next,
CD45+ cells (Fig. 2D) were gated for expression of CD11b,
followed by Ly6G and Ly6C to distinguish neutrophils and
monocytes, respectively (Fig. 2E and F) [19]. CD45+ cells were
also gated for expression of TCR-b and CD19 to distinguish
T cells and B cells, respectively (Fig. 2G). At 6 h after
PC3 administration, the majority of CD45+ leukocytes were
CD45+CD11b+Ly6G+Ly6Cint neutrophils (1 mg/kg: 72.9 6 9.2%;
5 mg/kg: 90.3 6 7%; n = 3; Fig. 2H). At the 14-h time point,
CD45+CD11b+Ly6G2Ly6Chi monocytes were the dominating
cell population in the CSF (1 mg/kg: 66.4 6 4.4%; n = 5; 5 mg/
kg: 64.3 6 1.8%; n = 10; Fig. 2I). Ly6G2Ly6Chi monocytes were
the most prevalent cell population at the 24-h time point (1
mg/kg: 54.5%; n = 7; 5 mg/kg: 51.6 6 2.7%; n = 8; Fig. 2J). No
signiﬁcant difference in CSF cell populations was observed
between the 2 doses of P3C at any time point (Fig. 2H–J;
P . 0.05).
P3C induces inﬁltration of leukocytes into the brain
To explore whether leukocytes are recruited to the brain after
P3C or LPS administration, ﬂow cytometry was performed on
whole brain tissue. CD11b+CD45hi cells were considered in-
ﬁltrating leukocytes, whereas resident microglia were
characterized as CD11b+CD45low as previously described [20].
P3C administration resulted in a signiﬁcantly higher proportion
of CD11b+CD45hi cells compared with control (P3C: 36 6 5% vs.
saline: 4.1 6 0.5%; P , 0.0001; n = 8–10/group), which indicated
increased inﬁltration of leukocytes into the brain (Fig. 3A and B).
In contrast, there was no signiﬁcant increase in the proportion of
CD11b+CD45hi cells in the brain after LPS administration (12.9
6 1.8%; P . 0.05; n = 8; Fig. 3A and B).
To conﬁrm ﬂow cytometry results and explore the anatomic
localization of CNS inﬁltrating leukocytes, we used Lys-EGFP-ki
mice, a strain the expresses EGFP under the control of the LysM
gene promoter, which is expressed in peripherally derived
myeloid cells, including monocytes and neutrophils, but not in
microglia [21]. In control animals (Fig. 3C–F), neutrophils
(EGFP+Ly6G+) were not detected and the few observable
EGFP+Ly6G2 cells, presumably monocytes, were localized within
the lumen of CD31+ blood vessels of meninges (Fig. 3D),
periventricular regions (Fig. 3E), and the choroid plexus (Fig. 3F).
LPS administration enhanced the presence of (EGFP+Ly6G2)
monocytes and macrophages in the subarachnoid space (Fig. 3G),
median eminence (Fig. 3H), periventricular endothelial cell
layer (Fig. 3I), and the choroid plexus (Fig. 3J). These cells
remained tightly associated with CD31+ blood vessels but, in some
B
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Figure 2. TLR2-induced CSF inﬁltrating cells are mainly neutrophils and inﬂammatory monocytes. PND8 mice were injected with P3C (1 or 5 mg/
kg, i.p.), and CSF was collected for ﬂow cytometry at 6, 14, or 24 h. (A–G) Representative images of ﬂow cytometry gating strategy on CSF depicting
cells in the CSF 14 h after injection of 5 mg/kg P3C. Live single cells were gated out and CD45+ cells were further analyzed for expression of T cell
(TCR-b+) and B cell (CD19+) markers, or gated for CD11b myeloid cells to be further analyzed for neutrophil (Ly6G+Ly6Cint) and monocyte
(Ly6G2Ly6Chi or Ly6G2Ly6Clow/int) markers. (H) CSF from 3 pups was pooled for each n at the 6-h time point (n = 3). (I and J) At 14 h (I) and
24 h (J), Ly6Chi inﬂammatory monocytes were the dominating cell population (n = 7–8). 7AAD =AQ:9 7-aminoactinomycin D, FSC = forward scatter, SSC
= side scatter. Data are presented as means 6 SD.
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Figure 3. Leukocyte inﬁltration into the brain after peripheral administration of TLR1/2 agonist. PND8 mice injected with LPS (0.3 mg/kg, i.p.) or
P3C (5 mg/kg i.p). Flow cytometry or immunohistochemistry was performed at 14 h. (A) Representative ﬂow cytometry plot showing an increase in
number of CD11b+CD45hi inﬁltrating inﬂammatory leukocytes after P3C but not after LPS injection. (B) Quantiﬁcation of ﬂow cytometry data.
(continued on next page)
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cases, displayed the morphologic characteristics of perivascular
macrophages and seemed to be localized outside the vessels (Fig.
3J, inset). LPS administration also resulted in the presence of
neutrophils within the vasculature of the choroid plexus (Fig. 3J).
P3C administration triggered a dramatic increase in neutrophils
and macrophages within the subarachnoid space (Fig. 3K),
median eminence (Fig. 3L), and the choroid plexus (Fig. 3N).
Both neutrophils and macrophages could be observed in
meningeal vessels (Fig. 3L) and within the CNS parenchyma (Fig.
3K and M). Accumulation of extravasated neutrophils and
macrophages in the choroid plexus of P3C-treated animals was
particularly striking (Fig. 3N). P3C did not induce Ly6G+
neutrophil inﬁltration into the brain in TLR2 2/2 micAQ:5 e
(Supplemental Fig. S1).
P3C and LPS provoke similar cellular inﬂammatory
response in circulation
To investigate the effect of TLR agonists on blood cellular
composition, we performed ﬂow cytometry on leukocytes from
mice treated with different doses of P3C and LPS. Analysis of
blood leukocytes revealed a relatively similar pattern of neutro-
phil response to both P3C and LPS. Between 6 and 24 h, both
P3C and LPS induced an increase in neutrophils compared with
saline-injected animals, followed by pronounced neutropenia at
48 h (Fig. 4). The proportion of CD11b+Ly6G2Ly6Chi monocytes
was decreased by P3C compared with saline-injected pups at all
time points studied. In contrast, LPS resulted in a more varied
response in this population of monocytes, with no difference
to control at the 14-h time point (Fig. 4). The proportion of
CD11b+Ly6G+Ly6Clow/int monocytes remained unaffected until
24 and 48 h after P3C or LPS administration, when there was a
signiﬁcant increase in the proportion of these cells (Fig. 4). The
proportion of CD19+ B cells generally decreased during the ﬁrst
24 h after both P3C and LPS administration. A small population
of TCR-b+ T cells (,10% of CD45+ cells) was detected in the
blood. The response in these cells was varied, but seemed to be
mostly reactive to LPS compared with P3C (Fig. 4).
P3C induces a distinct cytokine proﬁle in the brain
To investigate the peripheral and CNS inﬂammatory responses,
we performed 23-plex cytokine assays on plasma, spleen, and
brain after treatment of neonatal mice with different doses of
LPS and P3C. LPS, at both low and high doses, elicited the most
potent peripheral cytokine response as measured in both plasma
(Fig. 5A, Supplemental Table S1) and spleen (Fig. 5B,
Supplemental Table S2). A more restricted response was noted in
P3C-treated animals, where MCP-1, IL-12 (p40), IL-10, and IL-5
were increased in plasma compared with controls (Fig. 5A). In
the spleen, MIP-1a, MCP-1, IL-12 (p40), IL-1a, IL-1b, and G-CSF
were increased after P3C compared with saline (Fig. 5B). In the
brain, 8 cytokines were increased after P3C compared with saline
(MIP-1a, MIP-1b, MCP-1, KC AQ:6, IL-12p40, IL12p70, IL-1a, and G-
CSF; Fig. 5C), whereas LPS triggered an increase in the release of
4 cytokines in the brain (RANTES, MCP-1, KC, and G-CSF; Fig
5C, Supplemental Table S3).
P3C increases the permeability of the BCSFB and BBB
To investigate whether P3C inﬂuences the properties of the BBB
and BCSFB, we performed a sucrose permeability test at 10 h
after P3C or LPS injection. Doses that caused the most similar
patterns of peripheral inﬂammation were selected for the test,
that is, 5 mg/kg P3C and 0.3 mg/kg LPS. P3C injections resulted
in an increase of CSF/plasma ratios (P3C: 0.325 6 0.015;
compared with saline: 0.179 6 0.010) and an increase in brain/
plasma ratios across all brain areas (ratios increased 1.39–1.47
times across brain regions compared with controls), which was
indicative of a particularly large increase in BCSFB permeability
(Fig. 6A). In contrast, LPS injection resulted in no change in
BCSFB or BBB permeability, nor did P3C signiﬁcantly change
barrier permeability in TLR22/2 mice (Supplemental Fig. S2).
(C–N) Representative confocal images of leukocytes in the subarachnoid spaces (C, G, K), median eminence (D, H, L), around the third ventricle (E, I,
M), and the choroid plexus (F, J, N) of the brain 14 h after P3C injection. Green stain is LysM-expressing myeloid cells, red stain is Ly6G+ neutrophils,
and gray stain is CD31+ endothelial cells. ****P # 0.0001, 1-way ANOVA with Dunnett’s post hoc test (n = 8–10/group).
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Figure 4. Cellular immune response in the circulation after P3C and LPS administration. PND8 mice were injected with P3C (1 or 5 mg/kg, i.p.),
LPS (0.3 or 1 mg/kg, i.p.), or saline. (A–D) Blood was sampled at 6 (A), 14 (B), 24 (C), and 48 h (D), and cell populations were determined by
ﬂow cytometry. Gating strategies are as shown in Fig. 2. Data are presented as means 6 SD. *P # 0.05; **P # 0.01; ***P # 0.001; ****P # 0.0001,
1-way ANOVA with Dunnett’s post hoc test calculating the difference in relation to the saline group (n = 5–10).
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DISCUSSION
Inﬂammation in the newborn infant is a well-established risk
factor for subsequent neurologic impairment, such as cerebral
palsy [2, 4]. Leukocyte inﬁltration into the CSF is a clinical
feature of meningitis or meningoencephalitis in newborns and
adults [22, 23], and there is an association between neonatal
meningitis and increased risk of cerebral palsy [24]. Sterile
pleocytosis, that is, increased CSF leukocyte count without
bacteria in the CSF, also occurs in newborn infants with, for
example, urinary tract bacterial infection [25, 26]. However, it
has been unclear how systemic bacterial infections are linked
to inﬂammatory responses in the CSF and developing brain.
Here, we present a pivotal pathway in which systemic activation
of TLR2 results in increased permeability of the BCSFB and
increased number of leukocytes in the CSF and brain
concurrent with a heightened inﬂammatory response in the
brain. We demonstrate that these effects are TLR2 and MyD88
dependent and not directly associated with overall peripheral
inﬂammation. In addition, the strong proinﬂammatory TLR4
ligand, LPS, did not result in pleocytosis. Speciﬁc TLR2-
mediated effects may be of importance for neurologic out-
come in the newborn, as we have previously shown that
repeated stimulation of TLR2 results in impaired brain
development [14] and that the gram-positive bacteria Staph-
ylococcus epidermidis induces brain injury in neonatal mice,
partly via TLR2-dependent pathways [27]. Furthermore, TLR2-
deﬁcient mice are protected from neonatal hypoxia-ischemia,
which further supports the importance of TLR2 in neonatal
brain injury [13].
TLR2 is expressed on the cell surface where it forms
heterodimers with either TLR1 or TLR6 [28]. Each heterodimer
demonstrates different ligand speciﬁcity, with TLR1/TLR2
dimers binding bacterial triacylated lipopeptides, such as P3C,
whereas TLR2/TLR6 dimers preferentially bind mycoplasmal
diacylated lipoproteins, such as FSL-1 [29]. In the present study,
FSL-1 did not cause leukocyte inﬁltration into the CSF, which
suggests that the TLRAQ:7 2-medicated effect on pleocytosis is via the
TLR1/TLR2 heterodimer.
Cellular composition of the CSF was characterized by an early
dominance of neutrophils, followed by larger populations of
Ly6G2Ly6Chi monocytes at both 14 and 24 h and a minor
increase in lymphocyte population at 24 h. This is in agreement
with basic immunology dogma that neutrophils are the ﬁrst to
arrive at an inﬂammation site, followed by macrophages
and lymphocytes [30]. Ly6G2Ly6Chi monocytes constitute a
small proportion of leukocytes in circulation and are rapidly
recruited to infection/inﬂammation site [31]; therefore, the
decrease in their frequency in circulation in response to P3C
might be a result of their inﬁltration into the inﬂamed organs
(e.g., the CNS), but also the incapability of bone marrow to
completely reconstitute their population during the acute
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Figure 5. Peripheral and CNS cytokine responses by P3C and LPS. PND8 mice were injected with P3C (1 or 5 mg/kg, i.p.), LPS (0.3 or 1 mg/kg,
i.p.), or saline. (A–C) Plasma (A), spleen (B), and brain (C) were collected 6 h after injection and analyzed by 23-plex cytokine assay. Radar charts show
the Log10 of cytokine concentration (pg/ml for plasma samples and pg/mg protein for spleen and brain samples). KC = XXAQ:10 XX. *P # 0.05; **P #
0.01; ***P # 0.001; ****P # 0.0001, 1-way ANOVA with Dunnett’s post hoc test calculating the difference in relation to saline group (n = 5/group).
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Figure 6. Increased permeability of BCSFB and BBB to sucrose after
P3C administration. PND8 mice were injected with P3C (5 mg/kg,
i.p.), LPS (0.3 mg/kg, i.p.), or saline. At 10 h after injection, the [14C]
sucrose permeability test was performed for CSF and different parts of
the brain (cortex, striatum/thalamus, cerebellum, and brainstem). Data
are presented as means 6 SD. ***P # 0.001; ****P # 0.0001, 1-way
ANOVA with Dunnett’s post hoc test calculating the difference in
relation to saline group (n = 16 for saline and P3C groups, and n = 8
for LPS group). Data are presented as means 6 SD.
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phase of inﬂammation [31]. In contrast, the proportion of
Ly6G2Ly6Cint/low monocytes increased with time in circula-
tion. This population of monocytes, also known as patrolling
monocytes, crawls on endothelial cells in circulation, moni-
toring for infection/inﬂammation signals [32]. In patients
with sepsis, CD14dimCD16+ monocytes—the homolog of mouse
Ly6G2Ly6Cint/low monocytes—increase in number in circula-
tion, and interestingly, express higher levels of TLR2 [33],
which suggests a potential connection between TLR signaling
and monocyte subset polarization.
The different effects of P3C and LPS on immune cells in the
CSF and inﬁltrating cells in the brain are intriguing. Both TLR
agonists induced a strong peripheral inﬂammation, which
suggests that pleocytosis is not a common feature of systemic
inﬂammation, but may be dependent on speciﬁc mechanisms in
the BCSFB or BBB. Alternatively, cells in the CNS (e.g.,
microglia) may release speciﬁc chemoattractants in response to
P3C that are different from LPS. In support of this, we found
differences in the inﬂammatory response in the brain after P3C
compared with LPS. In particular, MIP-1a (human synonym
CCL3) emerged as the most differentially expressed cytokine in
the brain after P3C injection compared with LPS. In support of
this, in vitro data show that monocytic cells release more MIP-1a
and for a longer time in response to P3C compared with LPS
[34]. MIP-1a is known to have a role as a chemoattractant in
recruiting monocytes and neutrophils to inﬂammation sites [35].
CCL3 is also detected in the CSF of individuals with bacterial
meningitis [36] and its neutralization in experimental meningitis
inhibits neutrophil recruitment to the CNS [37]. Expression of
MIP-1a in the CNS could potentially attract cells and might, in
part, explain the difference between P3C and LPS in causing
inﬁltration of cells into the brain.
It should also be noted that one source of released cytokines
can be the inﬁltrated cells themselves creating an inﬂammation-
amplifying loop [38]. Although LPS caused release of RANTES
and MCP-1 in the brain, this did not lead to signiﬁcant leukocyte
transmigration, which suggests that other factors than chemo-
taxis, for example, barrier structure remodeling, are required.
Inﬁltrating immune cells in brain tissue were localized to areas
with close proximity to CSF-ﬁlled compartments, such as the
circumventricular organs and the choroid plexus. The choroid
plexus constitutes the BCSFB and could potentially play a role in
cell inﬁltration into CSF. In support of this, we found that P3C
induced a change in permeability, which was particularly
prominent in this barrier. A similar effect was not observed after
LPS, which indicated the BCSFB as a potentially major route of
leukocyte entry after TLR2 activation. The difference in P3C and
LPS effect is unlikely to be the result of different expressions of
their corresponding receptors, as both TLR2 and TLR4 are
known to be expressed in the choroid plexus [16, 39]. Whether
the change in barrier properties is a result of the direct effect of
P3C or secondary to transmigration of leukocytes warrants
further investigation.
In summary, we report for the ﬁrst time, to our knowledge, a
TLR2-dependent leukocyte inﬁltration into the CSF and CNS of
neonatal mice, largely through the BCSFB. Cell trafﬁcking was
not dependent on the degree of peripheral inﬂammation, as
TLR4 activation by LPS did not result in signiﬁcant cell
inﬁltration despite eliciting a similar or higher inﬂammatory
response in the circulation and spleen. The TLR2 agonist, P3C,
induced release of chemokines, such as MIP-1a, in the brain that
might be involved in recruiting leukocytes to the CNS. It also
increased BCSFB permeability, which may facilitate leukocyte
transmigration into the CSF. Altogether, this study describes an
intriguing difference in TLR2- vs. TLR4-mediated inﬂammation
on leukocyte trafﬁcking into the immature brain.
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